arrow_back Back Filing freshness 20-F Q4 FY2026 SEC EDGAR

C21 Investments Inc.

CXXIF
Price unavailable
Materials ·Medicinal Chemicals & Botanical Products ·USMedicinal Chemicals & Botanical Products
10 Visible periods
4 Metrics
Peer-ranked Benchmarks
Price Chart
46
Health
Weak
Bearish
auto_awesome

Analytical Summary

C21 Investments Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth
Op. Margin
ROIC
FCF / Share
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close.
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
38
Returns
25
Financial Health
83

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 10 quarters